| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 313.4 | 285.6 | 244.4 |
| Other income | 8.3 | 9.6 | 8.5 |
| Total income | 321.7 | 295.2 | 252.9 |
| Profit before exceptional items & tax | 75.1 | 75.5 | 40.6 |
| Profit before tax | 75.1 | 75.5 | 40.6 |
| Net profit | 53.3 | 51.4 | 28.6 |
| Operating margin | 23.3% | 25.6% | 16.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +86.40% |
|---|---|
| Net profit, quarter on quarter | +3.70% |
| Revenue, year on year | +28.20% |
| Operating profit, year on year | +108.10% |
| Operating profit, quarter on quarter | +1.40% |
BSE results filing, NSE: BLISSGVS. Figures extracted from the filing.
Bliss GVS Pharma Ltd: key numbers
- Share price
- ₹647.50
- Market cap
- ₹6,888 Cr
- Revenue (annual)
- ₹927.1 Cr
- Net profit (annual)
- ₹129.1 Cr
- P/E (TTM)
- 42.7×Sector 45.9×
- Promoter holding
- 50.07%+15.06% QoQ
- FII holding
- 5.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bliss GVS Pharma Ltd
All →Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bliss GVS Pharma Board Meeting Date
Bliss GVS Pharma Ltd scheduled a board meeting for October 29, 2026, to approve the company's unaudited financial results for the quarter ending September 30, 2026.
Bliss GVS Pharma Other Announcement
Bliss GVS Pharma Ltd has filed its quarterly shareholding pattern report for the period ended September 30, 2026.
Bliss GVS Pharma Annual General Meeting
Bliss GVS Pharma has issued a postal ballot notice to seek member approval for the appointment of three directors. This follows a recent change in control.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma Limited allotted 53,500 equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's total paid-up share capital.
Bliss GVS Pharma Promoter Reclassification
Bliss GVS Pharma announced the reclassification of its erstwhile promoter group to the public category following a change in control via an open offer.